"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A study looking at why some people take longer than others to be diagnosed with myeloma or lymphoma
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at people who have been told they have myeloma or lymphoma. This study is supported by Cancer Research UK as part of the National Awareness and Early Detection Initiative (NAEDI).
Researchers know that the time it takes to find out if someone has cancer can vary a lot. They want to know why this is. In this study they are looking at people who have been told they have myeloma or lymphoma.
The aims of this study are to
- Find out why it takes longer to diagnose myeloma or lymphoma in some people than others
- Find ways to speed up the time it takes to diagnose myeloma or lymphoma
Who can enter
This study will recruit about 65 people who have been recently diagnosed with myeloma or lymphoma.
During an interview a researcher will ask about your experiences from the time you first went to your doctor (
You don’t need to make any extra visits to hospital for this study. If you’ve recently been diagnosed with myeloma or lymphoma, a researcher will contact you by post, or in the hospital clinic. If you agree to join the study, they will arrange an interview at a place convenient to you, for example, at the hospital where you are being seen, or in your own home. The interview will take about an hour.
There are no side effects from taking part in this study. But you may find it hard to talk about your experiences. If this happens, the researcher will offer to stop the interview and continue at another time. And they will offer you further support if you would like it.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Debra Howell
National Awareness and Early Diagnosis Initiative (NAEDI)
NIHR Clinical Research Network: Cancer
University of York
Yorkshire and Humberside Haematology Network